Early Use of PCSK9 Inhibitors in the Prognosis of Patients with Acute Coronary Syndrome by Protecting Vascular Endothelial Function

2.

Nardin

M

,

Verdoia

M

,

Laera

N

,

Cao

D

,

De Luca

G

.

New insights into pathophysiology and new risk factors for ACS

.

J Clin Med

.

2023

;

12

(

8

):

2883

.

3.

Boulos

PK

,

Messenger

JC

,

Waldo

SW

.

Readmission after ACS: burden, epidemiology, and mitigation

.

Curr Cardiol Rep

.

2022

;

24

(

7

):

807

–

15

.

4.

Du

L

,

Cheng

Z

,

Zhang

Y

,

Li

Y

,

Mei

D

.

The impact of medication adherence on clinical outcomes of coronary artery disease: a meta-analysis

.

Eur J Prev Cardiol

.

2017

;

24

(

9

):

962

–

70

.

5.

Kaasenbrood

L

,

Boekholdt

SM

,

van der Graaf

Y

,

Ray

KK

,

Peters

RJ

,

Kastelein

JJ

, et al.

Distribution of estimated 10-year risk of recurrent vascular events and residual risk in a secondary prevention population

.

Circulation

.

2016

;

134

(

19

):

1419

–

29

.

6.

Badimon

L

,

Vilahur

G

.

Thrombosis formation on atherosclerotic lesions and plaque rupture

.

J Intern Med

.

2014

;

276

(

6

):

618

–

32

.

7.

Stone

GW

,

Maehara

A

,

Lansky

AJ

,

de Bruyne

B

,

Cristea

E

,

Mintz

GS

, et al.

A prospective natural-history study of coronary atherosclerosis

.

N Engl J Med

.

2011

;

364

(

3

):

226

–

35

.

8.

Ahmadi

A

,

Argulian

E

,

Leipsic

J

,

Newby

DE

,

Narula

J

.

From subclinical atherosclerosis to plaque progression and acute coronary events: JACC state-of-the-art review

.

J Am Coll Cardiol

.

2019

;

74

(

12

):

1608

–

17

.

9.

Dhaun

N

,

Webb

DJ

.

Endothelins in cardiovascular biology and therapeutics

.

Nat Rev Cardiol

.

2019

;

16

(

8

):

491

–

502

.

10.

Madigan

M

,

Zuckerbraun

B

.

Therapeutic potential of the nitrite-generated NO pathway in vascular dysfunction

.

Front Immunol

.

2013

;

4

:

174

.

11.

Cyr

AR

,

Huckaby

LV

,

Shiva

SS

,

Zuckerbraun

BS

.

Nitric oxide and endothelial dysfunction

.

Crit Care Clin

.

2020

;

36

(

2

):

307

–

21

.

12.

McEniery

CM

,

Qasem

A

,

Schmitt

M

,

Avolio

AP

,

Cockcroft

JR

,

Wilkinson

IB

.

Endothelin-1 regulates arterial pulse wave velocity in vivo

.

J Am Coll Cardiol

.

2003

;

42

(

11

):

1975

–

81

.

13.

Choi

KA

,

Kim

JH

,

Ryu

K

,

Kaushik

N

.

Current nanomedicine for targeted vascular disease treatment: trends and perspectives

.

Int J Mol Sci

.

2022

;

23

(

20

):

12397

.

14.

Bentzon

JF

,

Otsuka

F

,

Virmani

R

,

Falk

E

.

Mechanisms of plaque formation and rupture

.

Circ Res

.

2014

;

114

(

12

):

1852

–

66

.

15.

Xue

J

,

Zhang

Z

,

Sun

Y

,

Jin

D

,

Guo

L

,

Li

X

, et al.

Research progress and molecular mechanisms of endothelial cells inflammation in vascular-related diseases

.

J Inflamm Res

.

2023

;

16

:

3593

–

617

.

16.

Sabatine

MS

.

PCSK9 inhibitors: clinical evidence and implementation

.

Nat Rev Cardiol

.

2019

;

16

(

3

):

155

–

65

.

17.

Sabatine

MS

,

Giugliano

RP

,

Keech

AC

,

Honarpour

N

,

Wiviott

SD

,

Murphy

SA

, et al.

Evolocumab and clinical outcomes in patients with cardiovascular disease

.

N Engl J Med

.

2017

;

376

(

18

):

1713

–

22

.

18.

Schwartz

GG

,

Steg

PG

,

Szarek

M

,

Bhatt

DL

,

Bittner

VA

,

Diaz

R

, et al.

Alirocumab and cardiovascular outcomes after acute coronary syndrome

.

N Engl J Med

.

2018

;

379

(

22

):

2097

–

107

.

19.

Ugovšek

S

,

Šebeštjen

M

.

Non-lipid effects of PCSK9 monoclonal antibodies on vessel wall

.

J Clin Med

.

2022

;

11

(

13

):

3625

.

20.

Byrne

RA

,

Rossello

X

,

Coughlan

JJ

,

Barbato

E

,

Berry

C

,

Chieffo

A

, et al.

2023 ESC Guidelines for the management of acute coronary syndromes

.

Eur Heart J

.

2023

;

44

(

38

):

3720

–

826

.

21.

Cen

M

,

Ouyang

W

,

Zhang

W

,

Yang

L

,

Lin

X

,

Dai

M

, et al.

MitoQ protects against hyperpermeability of endothelium barrier in acute lung injury via a Nrf2-dependent mechanism

.

Redox Biol

.

2021

;

41

:

101936

.

22.

Wang

L

,

Cao

Y

,

Gorshkov

B

,

Zhou

Y

,

Yang

Q

,

Xu

J

, et al.

Ablation of endothelial Pfkfb3 protects mice from acute lung injury in LPS-induced endotoxemia

.

Pharmacol Res

.

2019

;

146

:

104292

.

23.

Huang

L

,

Li

Y

,

Cheng

Z

,

Lv

Z

,

Luo

S

,

Xia

Y

.

PCSK9 promotes endothelial dysfunction during sepsis via the TLR4/MyD88/NF-κB and NLRP3 pathways

.

Inflammation

.

2023

;

46

(

1

):

115

–

28

.

24.

Xing

JH

,

Li

R

,

Gao

YQ

,

Wang

MY

,

Liu

YZ

,

Hong

J

, et al.

NLRP3 inflammasome mediate palmitate-induced endothelial dysfunction

.

Life Sci

.

2019

;

239

:

116882

.

25.

D'Onofrio

N

,

Prattichizzo

F

,

Marfella

R

,

Sardu

C

,

Martino

E

,

Scisciola

L

, et al.

SIRT3 mediates the effects of PCSK9 inhibitors on inflammation, autophagy, and oxidative stress in endothelial cells

.

Theranostics

.

2023

;

13

(

2

):

531

–

42

.

26.

Martino

E

,

D’Onofrio

N

,

Balestrieri

A

,

Mele

L

,

Sardu

C

,

Marfella

R

, et al.

MiR-15b-5p and PCSK9 inhibition reduces lipopolysaccharide-induced endothelial dysfunction by targeting SIRT4

.

Cell Mol Biol Lett

.

2023

;

28

(

1

):

66

.

27.

Zulkapli

R

,

Muid

SA

,

Wang

SM

,

Nawawi

H

.

PCSK9 inhibitors reduce PCSK9 and early atherogenic biomarkers in stimulated human coronary artery endothelial cells

.

Int J Mol Sci

.

2023

;

24

(

6

):

5098

.

28.

Bhatt

DL

,

Lopes

RD

,

Harrington

RA

.

Diagnosis and treatment of acute coronary syndromes: a review

.

Jama

.

2022

;

327

(

7

):

662

–

75

.

29.

Jernberg

T

,

Hasvold

P

,

Henriksson

M

,

Hjelm

H

,

Thuresson

M

,

Janzon

M

.

Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective

.

Eur Heart J

.

2015

;

36

(

19

):

1163

–

70

.

30.

Gallego-Colon

E

,

Daum

A

,

Yosefy

C

.

Statins and PCSK9 inhibitors: a new lipid-lowering therapy

.

Eur J Pharmacol

.

2020

;

878

:

173114

.

31.

Kasichayanula

S

,

Grover

A

,

Emery

MG

,

Gibbs

MA

,

Somaratne

R

,

Wasserman

SM

, et al.

Clinical pharmacokinetics and pharmacodynamics of evolocumab, a PCSK9 inhibitor

.

Clin Pharmacokinet

.

2018

;

57

(

7

):

769

–

79

.

32.

Navarese

EP

,

Kolodziejczak

M

,

Kereiakes

DJ

,

Tantry

US

,

O'Connor

C

,

Gurbel

PA

.

Proprotein convertase subtilisin/kexin type 9 monoclonal antibodies for acute coronary syndrome: a narrative review

.

Ann Intern Med

.

2016

;

164

(

9

):

600

–

7

.

33.

Paciullo

F

,

Momi

S

,

Gresele

P

.

PCSK9 in haemostasis and thrombosis: possible pleiotropic effects of PCSK9 inhibitors in cardiovascular prevention

.

Thromb Haemost

.

2019

;

119

(

3

):

359

–

67

.

34.

Momtazi-Borojeni

AA

,

Sabouri-Rad

S

,

Gotto

AM

,

Pirro

M

,

Banach

M

,

Awan

Z

, et al.

PCSK9 and inflammation: a review of experimental and clinical evidence

.

Eur Heart J Cardiovasc Pharmacother

.

2019

;

5

(

4

):

237

–

45

.

35.

Ziogos

E

,

Chelko

SP

,

Harb

T

,

Engel

M

,

Vavuranakis

MA

,

Landim-Vieira

M

, et al.

Platelet activation and endothelial dysfunction biomarkers in acute coronary syndrome: the impact of PCSK9 inhibition

.

Eur Heart J Cardiovasc Pharmacother

.

2023

;

9

(

7

):

636

–

46

.

36.

Zhang

Y

,

Zhang

Y

,

Zhang

B

,

Chen

Z

,

Wei

Y

,

Chen

P

, et al.

Early initiation of evolocumab treatment in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention

.

Clin Ther

.

2022

;

44

(

6

):

901

–

12

.

37.

Mach

F

,

Baigent

C

,

Catapano

AL

,

Koskinas

KC

,

Casula

M

,

Badimon

L

, et al.

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

.

Eur Heart J

.

2020

;

41

(

1

):

111

–

88

.

38.

Leucker

TM

,

Gerstenblith

G

,

Schär

M

,

Brown

TT

,

Jones

SR

,

Afework

Y

, et al.

Evolocumab, a PCSK9-monoclonal antibody, rapidly reverses coronary artery endothelial dysfunction in people living with HIV and people with dyslipidemia

.

J Am Heart Assoc

.

2020

;

9

(

14

):

e016263

.

39.

Di Minno

A

,

Gentile

M

,

Iannuzzo

G

,

Calcaterra

I

,

Tripaldella

M

,

Porro

B

, et al.

Endothelial function improvement in patients with familial hypercholesterolemia receiving PCSK-9 inhibitors on top of maximally tolerated lipid lowering therapy

.

Thromb Res

.

2020

;

194

:

229

–

36

.

40.

Spence

JD

,

Urquhart

BL

.

Cerebrovascular disease, cardiovascular disease, and chronic kidney disease: interplays and influences

.

Curr Neurol Neurosci Rep

.

2022

;

22

(

11

):

757

–

66

.

41.

Deminice

R

,

Silva

TC

,

de Oliveira

VH

.

Elevated homocysteine levels in human immunodeficiency virus-infected patients under antiretroviral therapy: a meta-analysis

.

World J Virol

.

2015

;

4

(

2

):

147

–

55

.

42.

Huang

A

,

Pinto

JT

,

Froogh

G

,

Kandhi

S

,

Qin

J

,

Wolin

MS

, et al.

Role of homocysteinylation of ACE in endothelial dysfunction of arteries

.

Am J Physiol Heart Circ Physiol

.

2015

;

308

(

2

):

H92

–

100

.

43.

Maruyama

I

,

Bell

CE

,

Majerus

PW

.

Thrombomodulin is found on endothelium of arteries, veins, capillaries, and lymphatics, and on syncytiotrophoblast of human placenta

.

J Cel Biol

.

1985

;

101

(

2

):

363

–

71

.

44.

Loghmani

H

,

Conway

EM

.

Exploring traditional and nontraditional roles for thrombomodulin

.

Blood

.

2018

;

132

(

2

):

148

–

58

.

45.

Weiler

H

,

Isermann

BH

.

Thrombomodulin

.

J Thromb Haemost

.

2003

;

1

(

7

):

1515

–

24

.

46.

Chen

TP

,

Lee

HL

,

Huang

YH

,

Hsieh

MJ

,

Chiang

WL

,

Kuo

WH

, et al.

Association of intercellular adhesion molecule-1 single nucleotide polymorphisms with hepatocellular carcinoma susceptibility and clinicopathologic development

.

Tumour Biol

.

2016

;

37

(

2

):

2067

–

74

.

47.

Barton

M

,

Yanagisawa

M

.

Endothelin: 30 Years from discovery to therapy

.

Hypertens (Dallas, Tex

.

1979). 2019

;

74

(

6

):

1232

–

65

.

48.

Vaughan

DE

.

PAI-1 and atherothrombosis

.

J Thromb Haemost

.

2005

;

3

(

8

):

1879

–

83

.

49.

Manz

XD

,

Bogaard

HJ

,

Aman

J

.

Regulation of VWF (von Willebrand factor) in inflammatory thrombosis

.

Arterioscler Thromb Vasc Biol

.

2022

;

42

(

11

):

1307

–

20

.

50.

Heiss

C

,

Rodriguez-Mateos

A

,

Bapir

M

,

Skene

SS

,

Sies

H

,

Kelm

M

.

Flow-mediated dilation reference values for evaluation of endothelial function and cardiovascular health

.

Cardiovascular Research

.

2023

;

119

(

1

):

283

–

93

.

51.

Tomiyama

H

,

Kohro

T

,

Higashi

Y

,

Takase

B

,

Suzuki

T

,

Ishizu

T

, et al.

Reliability of measurement of endothelial function across multiple institutions and establishment of reference values in Japanese

.

Atherosclerosis

.

2015

;

242

(

2

):

433

–

42

.

52.

Maruhashi

T

,

Kajikawa

M

,

Kishimoto

S

,

Hashimoto

H

,

Takaeko

Y

,

Yamaji

T

, et al.

Diagnostic criteria of flow-mediated vasodilation for normal endothelial function and nitroglycerin-induced vasodilation for normal vascular smooth muscle function of the brachial artery

.

J Am Heart Assoc

.

2020

;

9

(

2

):

e013915

.

53.

Landmesser

U

,

Bahlmann

F

,

Mueller

M

,

Spiekermann

S

,

Kirchhoff

N

,

Schulz

S

, et al.

Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans

.

Circulation

.

2005

;

111

(

18

):

2356

–

63

.

54.

Dogra

GK

,

Watts

GF

,

Herrmann

S

,

Thomas

MA

,

Irish

AB

.

Statin therapy improves brachial artery endothelial function in nephrotic syndrome

.

Kidney Int

.

2002

;

62

(

2

):

550

–

7

.

55.

Bianconi

V

,

Mannarino

MR

,

Cosentini

E

,

Figorilli

F

,

Colangelo

C

,

Cellini

G

, et al.

The impact of statin therapy on in-hospital prognosis and endothelial function of patients at high-to-very high cardiovascular risk admitted for COVID-19

.

J Med Virol

.

2023

;

95

(

3

):

e28678

.

56.

Zhang

L

,

Gong

D

,

Li

S

,

Zhou

X

.

Meta-analysis of the effects of statin therapy on endothelial function in patients with diabetes mellitus

.

Atherosclerosis

.

2012

;

223

(

1

):

78

–

85

.

57.

Katsiki

N

,

Reiner

Ž

,

Tedeschi Reiner

E

,

Al-Rasadi

K

,

Pirro

M

,

Mikhailidis

DP

, et al.

Improvement of endothelial function by pitavastatin: a meta-analysis

.

Expert Opin Pharmacother

.

2018

;

19

(

3

):

279

–

86

.

58.

Martínez-González

J

,

Badimon

L

.

Influence of statin use on endothelial function: from bench to clinics

.

Curr Pharm Des

.

2007

;

13

(

17

):

1771

–

86

.

59.

Omer

MA

,

Tyler

JM

,

Henry

TD

,

Garberich

R

,

Sharkey

SW

,

Schmidt

CW

, et al.

Clinical characteristics and outcomes of STEMI patients with cardiogenic shock and cardiac arrest

.

JACC Cardiovasc Interv

.

2020

;

13

(

10

):

1211

–

9

.

60.

Hao

Y

,

Yang

YL

,

Wang

YC

,

Li

J

.

Effect of the early application of evolocumab on blood lipid profile and cardiovascular prognosis in patients with extremely high-risk acute coronary syndrome

.

Int Heart J

.

2022

;

63

(

4

):

669

–

77

.

61.

Karki

P

,

Birukov

KG

.

Lipid mediators in the regulation of endothelial barriers

.

Tissue barriers

.

2018

;

6

(

1

):

e1385573

.

62.

Goldberg

IJ

,

Bornfeldt

KE

.

Lipids and the endothelium: bidirectional interactions

.

Curr Atheroscler Rep

.

2013

;

15

(

11

):

365

.

63.

Ouweneel

AB

,

Van Eck

M

.

Lipoproteins as modulators of atherothrombosis: from endothelial function to primary and secondary coagulation

.

Vascul Pharmacol

.

2016

;

82

:

1

–

10

.

64.

Sugiura

T

,

Dohi

Y

,

Yamashita

S

,

Yamamoto

K

,

Wakamatsu

Y

,

Tanaka

S

, et al.

Impact of lipid profile and high blood pressure on endothelial damage

.

J Clin Lipidol

.

2011

;

5

(

6

):

460

–

6

.

65.

Yang

PT

,

Li

Y

,

Wang

JG

,

Zhang

LJ

,

Yang

SQ

,

Tang

L

, et al.

The association of remnant cholesterol with endothelial dysfunction and subclinical atherosclerosis in a check-up population in China

.

J Atheroscler Thromb

.

2023

;

30

(

6

):

684

–

97

.

66.

Schremmer

J

,

Busch

L

,

Baasen

S

,

Heinen

Y

,

Sansone

R

,

Heiss

C

, et al.

Chronic PCSK9 inhibitor therapy leads to sustained improvements in endothelial function, arterial stiffness, and microvascular function

.

Microvasc Res

.

2023

;

148

:

104513

.

67.

Philpott

AC

,

Hubacek

J

,

Sun

YC

,

Hillard

D

,

Anderson

TJ

.

Niacin improves lipid profile but not endothelial function in patients with coronary artery disease on high dose statin therapy

.

Atherosclerosis

.

2013

;

226

(

2

):

453

–

8

.

68.

Mitani

H

,

Egashira

K

,

Ohashi

N

,

Yoshikawa

M

,

Niwa

S

,

Nonomura

K

, et al.

Preservation of endothelial function by the HMG-CoA reductase inhibitor fluvastatin through its lipid-lowering independent antioxidant properties in atherosclerotic rabbits

.

Pharmacology

.

2003

;

68

(

3

):

121

–

30

.

69.

Steinberg

FM

,

Guthrie

NL

,

Villablanca

AC

,

Kumar

K

,

Murray

MJ

.

Soy protein with isoflavones has favorable effects on endothelial function that are independent of lipid and antioxidant effects in healthy postmenopausal women

.

Am J Clin Nutr

.

2003

;

78

(

1

):

123

–

30

.

70.

Gomez-Pastor

R

,

Burchfiel

ET

,

Thiele

DJ

.

Regulation of heat shock transcription factors and their roles in physiology and disease

.

Nat Rev Mol Cel Biol

.

2018

;

19

(

1

):

4

–

19

.

71.

Martindale

JL

,

Holbrook

NJ

.

Cellular response to oxidative stress: signaling for suicide and survival

.

J Cel Physiol

.

2002

;

192

(

1

):

1

–

15

.

72.

Metzler

B

,

Abia

R

,

Ahmad

M

,

Wernig

F

,

Pachinger

O

,

Hu

Y

, et al.

Activation of heat shock transcription factor 1 in atherosclerosis

.

Am J Pathol

.

2003

;

162

(

5

):

1669

–

76

.

73.

Uchiyama

T

,

Atsuta

H

,

Utsugi

T

,

Oguri

M

,

Hasegawa

A

,

Nakamura

T

, et al.

HSF1 and constitutively active HSF1 improve vascular endothelial function (heat shock proteins improve vascular endothelial function)

.

Atherosclerosis

.

2007

;

190

(

2

):

321

–

9

.

74.

Wang

D

,

He

S

,

Zhong

G

,

Meng

J

,

Bi

Q

,

Tu

R

.

Effects of heat shock protein 90 on complement activation in myocardial ischemia/reperfusion injury after pioglitazone preconditioning

.

Adv Clin Exp Med

.

2023

;

32

(

12

):

1401

–

12

.

75.

Zhang

XY

,

Huang

Z

,

Li

QJ

,

Zhong

GQ

,

Meng

JJ

,

Wang

DX

, et al.

Role of HSP90 in suppressing TLR4-mediated inflammation in ischemic postconditioning

.

Clin Hemorheol Microcirc

.

2020

;

76

(

1

):

51

–

62

.

76.

Cheng

XF

,

He

ST

,

Zhong

GQ

,

Meng

JJ

,

Wang

M

,

Bi

Q

, et al.

Exosomal HSP90 induced by remote ischemic preconditioning alleviates myocardial ischemia/reperfusion injury by inhibiting complement activation and inflammation

.

BMC Cardiovasc Disord

.

2023

;

23

(

1

):

58

.

77.

Uchiyama

T

,

Atsuta

H

,

Utsugi

T

,

Ohyama

Y

,

Nakamura

T

,

Nakai

A

, et al.

Simvastatin induces heat shock factor 1 in vascular endothelial cells

.

Atherosclerosis

.

2006

;

188

(

2

):

265

–

73

.